Exact Sciences (EXAS) has quietly put in a very strong past 3 months, with a roughly 75% total return and 81% over the past year, putting fresh attention on its cancer testing business. See our latest ...
ComboMATCH trials will use Exact Sciences' (EXAS) new OncoExTra™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials ...
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results